Skip to content
Open access

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma

Aug 2026 · Research Square · 0 citations · 46 references
Medicine

TL;DR

Distinct signatures in the adjuvant and metastatic settings suggest differences in T-cell programs associated with patient outcomes, and support further evaluation of pre-treatment circulating T-cell transcriptional profiles as predictors of ICI response and toxicity in melanoma.

Abstract

Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with melanoma and are now the standard of care for high-risk and advanced disease. However, long-term benefits are observed in only around 25% of patients, with significant risk for immune-related adverse events, highlighting the need for predictive biomarkers. To develop a minimally invasive, pre-treatment biomarker strategy, we profiled functional and subset-specific transcripts in peripheral blood T lymphocytes (PBTLs) and applied machine learning to identify predictive signatures. Patients were enrolled prior to receiving ICI monotherapy in the adjuvant (Exploratory n=61, Validation=78) or metastatic (Exploratory n=48, Validation=46) settings. Following feature selection, random forest models were trained and benchmarked against empirical null models. In the adjuvant setting, CD160 and GZMB predicted recurrence (95th percentile), while treatment-limiting toxicity was predicted by a signature comprising TNFRSF18, VTCN1, TIGIT, CCR4, and AHR (97th percentile). In the metastatic setting, baseline CD45RB, a marker of T-cell differentiation, most strongly predicted progression within one year (93.9th percentile). Distinct signatures in the adjuvant and metastatic settings suggest differences in T-cell programs associated with patient outcomes. These findings support further evaluation of pre-treatment circulating T-cell transcriptional profiles as predictors of ICI response and toxicity in melanoma.

Read PDF

Similar papers

Review Open access Sep 2026

Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of TNBC, leading to durable responses and improved survival. With the adoption of immunotherapy into high-risk early-stage and selected metastatic triple-negative breast cancer (TNBC), clinicians’ ability to recognize and treat immune-related adverse...

E. McGillivray, Savannah Kane, Armina Saadatkhah et al. · 0 citations
Open access Sep 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

F fibrovascular and myeloid reprogramming is establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.

N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al. · 0 citations
Review Open access Sep 2026

The next-generation biomarkers in early-stage triple negative breast cancer.

Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.

Federica Falcone, E. Pietroluongo, P. De Placido · 0 citations
Open access Sep 2026

Identification of biomarkers associated with enhanced survival in lung cancer patients undergoing immune checkpoint inhibitor treatment.

Findings suggest that biomarkers reflecting reduced inflammation, absence of metastasis and potentially improved nutritional status may be associated with improved PFS and OS in patients with advanced NSCLC receiving ICIs.

Ilse Visser, E. Suazo-Zepeda, T. J. N. Hiltermann et al. · 0 citations
Open access Sep 2026

63 Th17 Signature Predicts Response to Dual Checkpoint Blockade in Metastatic Renal Cell Carcinoma

Abstract Background Combination immune checkpoint inhibition with anti-CTLA-4 and anti-PD-1 antibodies improves outcomes in metastatic renal cell carcinoma (mRCC), yet 40–60% of patients fail to achieve meaningful responses. Robust biomarkers that predict deep and durable responses are lacking. We aimed to define syste...

S. Guglietta, A. Bärenwaldt, Anthony Sonrel et al. · 0 citations
Review Open access Oct 2026

Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer.

This review will analyze the current evidence supporting established predictive biomarkers, including PD-L1 expression, while highlighting their major limitations, and discuss and summarize emerging clinical and molecular biomarkers and integrative predictive approaches aimed at improving the stratification of patients...

C. Spagnolo, I. Campo, Elena Fassi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.